Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Receivables (2016 - 2025)

Cumberland Pharmaceuticals' Change in Receivables history spans 16 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 1566.71% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $5.2 million, up 169.82%, while the annual FY2025 figure was $5.2 million, 169.82% up from the prior year.
  • Change in Receivables for Q4 2025 was $6.5 million at Cumberland Pharmaceuticals, up from $113691.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.8 million in Q1 2022 and bottomed at -$3.4 million in Q2 2021.
  • The 5-year median for Change in Receivables is $113691.0 (2025), against an average of $430603.8.
  • The largest annual shift saw Change in Receivables plummeted 262.39% in 2021 before it skyrocketed 4421.45% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$3.0 million in 2021, then soared by 30.41% to -$2.1 million in 2022, then soared by 76.72% to -$481613.0 in 2023, then surged by 181.15% to $390841.0 in 2024, then soared by 1566.71% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Change in Receivables are $6.5 million (Q4 2025), $113691.0 (Q3 2025), and -$171014.0 (Q2 2025).